Padma 1995.

Methods	Randomized controlled trial Duration: dates not specified. Participants followed up for 3 months.
Participants	Number: 29 enrolled (22 male, 7 female) Inclusion criteria: adults and children aged 8 to 50 with multiple cystic lesions suggestive of neurocysticercosis plus neurological signs Exclusion criteria: calcified lesions only Type of lesion: degenerating, viable or mixed (possible to follow the radiological clearance of individual lesions by type)
Interventions	Group 1. Albendazole: 15 mg per kg per day for 7 days Group 2. Placebo
Outcomes	Included in the review: change in number of lesions at 1 and 3 months; persistence of lesions at 1 week, 1 month, and 3 months Not included in the review: change in oedema at 1 and 3 months
Notes	Location: India Source of funding: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Quote: "We undertook a randomized, double‐blind, placebo‐controlled study" Decision: unclear, probably done
Allocation concealment?	Unclear risk	Not described Decision: unclear
Blinding? All outcomes	Low risk	Quote: "...double‐blind, placebo‐controlled study"... "Placebo tablets of similar appearance"..."The CTS scans were assessed...by a neuroradiologist who was not aware of the treatment given" Decision: done
Incomplete outcome data addressed? All outcomes	Low risk	29 randomized, 29 included in the analysis (100%)
Free of selective reporting?	Low risk	No evidence of selective reporting
Free of other bias?	Low risk	No evidence of selective reporting